Press Releases

Stirling, UK and Boston, USA – [27 November 2024] – Symbiosis Pharmaceutical Services, a world-class Contract Manufacturing Organisation (CMO), specializing in sterile GMP manufacturing of biopharmaceuticals, has announced the expansion of its Business Development team with the addition of two highly experienced U.S. Business Development Directors: Jacqueline Towell, who will oversee the US West Coast region, and Cindy Koonce, who will focus on the US East Coast.

Both Jacqueline and Cindy bring a wealth of expertise from the pharmaceutical and biotechnology sectors, further strengthening Symbiosis’ ability to support clients across North America and reinforcing its commitment to providing high-quality, rapid-turnaround fill-finish manufacturing services for biopharmaceutical products.

Jacqueline joins Symbiosis with over 12 years of experience in the Contract Development and Manufacturing Organization (CDMO) space, having worked at leading firms including Alcami, Patheon and Pii. 

Based in Southern California, her role at Symbiosis will focus on driving business development and managing strategic accounts in the US West Coast region. 

“My background in technical solutions, client relationship management, and contract negotiations will be instrumental in continuing Symbiosis’ growth and solidifying its position within the expanding biologics and advanced therapies market” said Jacqueline.

“I will be using my expertise to enhance Symbiosis’ ability to meet the increasing demand for high-quality drug product manufacturing, especially for biologics, advanced therapies, and gene-based medicines. These are exciting times!”

Cindy, based in Wilmington, NC, brings over 20 years of business development experience in the pharmaceutical industry, having held roles at Alcami, Pii and most recently Infinity Laboratories.

Cindy will focus on the US East Coast region, where she will be responsible for driving new business opportunities and managing existing client relationships. She added: “I have a customer-centric approach and a deep understanding of the industry - both of which align perfectly with Symbiosis’ goal of offering outstanding customer service and high-quality manufacturing solutions.”

Both appointments come at a key time for Symbiosis’ growth strategy, as the company continues its expansion with a new state-of-the-art automated sterile manufacturing facility, close to its existing facilities in Stirling, Scotland, set to be fully commissioned in early 2025 following regulatory inspection. This will increase the company’s commercial scale sterile manufacturing capabilities, enabling it to serve a growing global client base.

“These appointments are a testament to our ongoing commitment to supporting our clients and growing our presence in the North American market,” commented Colin MacKay, CEO of Symbiosis Pharmaceutical Services.

“Both Jacqueline and Cindy bring valuable industry experience and a track record of success in business development. Their expertise will allow us to unlock new opportunities and better serve our clients in key regions, while continuing to expand our capabilities globally.”

The expansion of Symbiosis’ business development team reflects the company’s broader strategy to enhance its client relationships, drive business growth, and meet the increasing demand for its GMP manufacturing services in the biopharmaceutical sector.

ENDS

About Symbiosis Pharmaceutical Services

Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines. 

The Symbiosis facility in Stirling, Scotland, was designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.

Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.

For more information on Symbiosis visit http://www.symbiosis-pharma.com or follow us on LinkedIn.

Media Contact:
Rachael Heath
ramarketing
rachael@ramarketingpr.com
www.ramarketingpr.com